Please login to the form below

Cardiovascular disease: The scale of the challenge

Many years in the making, the first CVDPREVENT audit report, published recently, gives a detailed snapshot of how those with cardiovascular diseases (CVD) are identified, diagnosed, and managed across England. In his latest blog, Hanover Health’s Mark MacDonald asks – what does this data tell us about the impact CVD is having on our collective health, how much are health inequalities a factor, and where are the opportunities for the system to collectively do better to prevent disease, disability, and death?

While COVID-19 continues to dominate the news and policy agenda, we recently saw an important milestone in our understanding of a more long-standing health challenge of our time: cardiovascular disease (CVD). As part of efforts set out in NHS England’s Long Term Plan to prevent 150,000 deaths over the next decade from the likes of heart attacks and strokes, the first CVDPREVENT audit has been published. Its findings around the scale of the challenge, as well as the opportunities for improvement it identifies, are stark.

It’s important to remind ourselves why taking action on CVD matters. CVD contributes to disability, death and hardship on a huge scale. Stroke alone is the single biggest cause of adult disability in the UK and not only devastates the lives of those affected but is associated with enormous cost to the health, social care and welfare system.

Thousands of cases of stroke, diabetes, heart failure and kidney disease could and should be prevented every year yet currently are not. As the audit reveals, too many people with high risk conditions such as atrial fibrillation – a type of irregular heartbeat associated with the most serious strokes and heart attacks – are either not being diagnosed or being poorly managed. Only two thirds of those with high blood pressure are being treated in line with clinical guidance, and how people are monitored and treated varies depending on sex, age and ethnicity. And when it comes to dealing with cholesterol, black people are the least likely to have been prescribed medication, despite what is known about the link between high cholesterol and heart attacks, for example.

It’s also clear that the range of conditions which fall under the CVD banner should not be viewed in isolation because chances are that if someone has one high risk condition for CVD, they will also be living with multiple other long-term conditions.

COVID-19 has shone a spotlight on how the burden of ill health is spread far from equally. This report – bringing together patient data from before the pandemic – reminds us yet again that we cannot make serious progress against the big killer diseases without recognising the role inequalities play in access to treatment and outcomes and CVD and its associated risk factors is no different.

But as the report makes clear, there are opportunities to change things, not least because CVD and its associated high risk conditions can be – in many cases – very effectively diagnosed and managed. Such are the numbers of people affected by CVD – 6.5 million have diagnosed hypertension in England alone – that even incremental improvements can make a world of difference. And just imagine the impact if we could find, diagnose and effectively manage the five million or so with undiagnosed hypertension, or the 85% of those who don’t know they have familial hypercholesterolaemia, a type of high cholesterol.

Encouragingly, the audit comes with new resources for local health systems to support their own quality improvement programmes, and there are real opportunities for ICSs, CCGs and others to work collaboratively – including with charities and industry – to make these a success and to share what works with others. Great work is already happening but it needs to be scaled up urgently.

This first CVDPREVENT audit is a significant milestone in supporting national and local systems assess and prioritise their work around these killer diseases. And while the data cover only England, decision-makers elsewhere in the UK should consider how doing something similar in their areas could help them too address one of the biggest health challenges of our time.

Building a clear picture of the scale of the challenge, as well as the opportunity to do better, is something which should continue to be a priority for policymakers, not least because CVD is such a key battleground in the fight against health inequalities and supporting those living with multiple long term conditions.

10th January 2022


Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Riverside House
Southwark Bridge House
United Kingdom

Latest content on this profile

Femtech: Transforming the future of women's healthcare
Femtech is potentially the most important development in health care right now. Women's health has been under-researched and overlooked for successive generations - it's time that government and industry get ready to deliver.
Hanover Communications
VPAS: The importance of making the right arguments, even in challenging times
With key workers’ strikes, inflation, and immense pressure on public services, arguing for a more generous pricing settlement for the pharmaceuticals industry could not be tougher. Read our Health Director James Mole’s thoughts on the support needed to protect the UK life sciences’ ambitions, despite the challenging backdrop.
Hanover Communications
Putting prevention at the heart of the future of the NHS
Prioritising the prevention of cardiovascular disease (CVD) should be at the heart of plans to safeguard the long-term sustainability of the NHS. Unfortunately, action in this area has to date not matched ambition, putting thousands of patients’ lives – and the future of the health system – at risk.
Hanover Communications
Action on Anti-microbial resistance: Will the UK rise to the challenge
Timely and effective antimicrobials are the cornerstone of our healthcare systems, providing life-saving treatment and supporting vital services like routine operations, transplants and cancer treatment. We are three years into the UK Government’s 20-Year Vision for Antimicrobial Resistance (AMR), and the Department of Health and Social Care recently launched a consultation for the next iteration of the AMR National Action Plan (2024-2029). However, latest figures show that AMR is still on the rise. Is UK policy ambitious enough to drive innovation in AMR, and is the Government on track to contain, control and mitigate AMR by 2040?
Hanover Communications
Winter and workforce woes: challenges facing the new Secretary of State for Health and Social Care
For the third time this year, the NHS and social care has a new Secretary of State. The appointment must now signal stability following a period of political turbulence, as we head into what health leaders are describing as the toughest winter to date. Backlogs, delayed discharges, ambulance and A&E pressures, and crumbling NHS estates will remain top of Steve Barclay’s priority list in the coming weeks and months ahead. However, he will also need to address the longstanding workforce issues that hold back both the NHS and social care sector. Only dealing with these structural challenges will ensure the health and care system is operationally fit for winters to come.
Hanover Communications
A new 10-year cancer plan: Will the government be able to deliver what the sector needs?
The Truss Government has committ­ed to developing a new 10-year cancer plan. But set against the backdrop of the Secretary of States priorities, what real value can the sector expect a new cancer plan to deliver? What questions need addressing to drive impactful change for patients? Will there be funding available to support the transformation?  We will explore the state of play of cancer care in England and assess the main priorities, including how they align with wider NHS challenges. We will set out the difficult choices that a new plan must confront to enable prioritisation of this complex disease area and consider the balance between taking action to impact patients now versus initiatives to benefit patients of the future.
Hanover Communications